BOLT Bolt Biotherapeutics
- 0.760
- -0.001-0.11%
- 0.754
- -0.006-0.78%
Bolt Biotherapeutics News
Earnings Call Summary | Bolt Biotherapeutics(BOLT.US) Q1 2024 Earnings Conference
The following is a summary of the Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript:Financial Performance:Bolt Biotherapeutics did not provide specific financial performance data duri
Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...
Bolt Biotherapeutics Cut to Market Perform From Outperform by Leerink Partners
Bolt Biotherapeutics Cut to Market Perform From Outperform by Leerink Partners
Express News | Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1
NTRB, AERT and SPWR Among Mid-day Movers
Express News | HC Wainwright & Co. Downgrades Bolt Biotherapeutics to Neutral
Wall Street Set to Open Modestly Higher Wednesday as Inflation Dips in April
US stocks look set to open modestly higher Wednesday as key monthly inflation data came in slightly lower than expected, while annual inflation matched analyst forecasts. The Dow Jones Industrial Aver
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Deutsche Ba
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod,
Bolt Biotherapeutics BOLT Program Discontinued; SINTX SINT Earnings
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.Arcutis Biotherapeutics
Top Premarket Decliners
Virpax Pharmaceuticals (VRPX) shares dropped nearly 61% in recent Wednesday premarket activity, continuing Tuesday's 25% loss. Bolt Biotherapeutics (BOLT) shares tumbled more than 31% after Guggenheim
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket
US stock futures were flat in Wednesday's premarket session as investors anxiously await key inflation data later in the morning. The Dow Jones Industrial Average futures were up 0.01%, S&P 500 future
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 d
Express News | Bolt Biotherapeutics Inc : Jonestrading Cuts to Hold
Express News | Bolt Biotherapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results. Also, Multiple Firms Downgraded Their Respective Price Targets on the Stock
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3.
Express News | Bolt Biotherapeutics Inc : Stifel Cuts Target Price to $1.5 From $6
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bolt Biotherapeutics (BOLT), Laboratory (LH) and Biophytis (OtherBPTSY)
Express News | Bolt Biotherapeutics Inc : Guggenheim Cuts to Neutral From Buy
Analysis
Price Target
No Data
